Aimovig

Active Ingredient(s): Erenumab-aooe
FDA Approved: * May 17, 2018
Pharm Company: * AMGEN INC
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Aimovig Overview

Erenumab (trade name Aimovig) is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.[1][2][3] It was the first of the group of CGRPR antagonists to be approved in 2018.[4] Contents 1 Uses 2 Pharmacology 3 History 3.1 Development 3.2 Approval and marketing 4 See also 5 References Uses Erenumab is approved for prevention of migraine in adults.[5] It is administered by subcutaneous injection of 70 or 140mg once a month.[6...

Read more Aimovig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Erenumab

Recent Aimovig Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Erenumab-aooe
  • Injection: 70mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aimovig: (2 results)

Sorted by National Drug Code
  • 55513-840 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc
  • 55513-841 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc

Other drugs which contain Erenumab-aooe or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 19 July 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.